Biocartis – Idylla for Colorectal Cancer
Biocartis Idylla™ for colorectal cancer
The Idylla solution is a revolutionary, fully automated, real-time PCR based molecular testing system designed to offer results in a minimum amount of time.
19Mar
News
14Jun
HistoCyte – The Role of Accurate Diagnostics
HistoCyte tissue controls are a testament to precision and reliability in cancer diagnosis.
02Feb
Blood soluble OX40 (CD134) levels in advanced colorectal cancer
Products are for professional/laboratory use only.
A recent publication in the oncology field revealed that high blood levels of soluble OX40 indicate reduced survival in patients with advanced colorectal cancer (CRC).
03Feb
Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy
Products are for professional/laboratory use only.
PRESS RELEASE: 28 August 2018
Mechelen, Belgium, 28 August 2018 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that it has obtained exclusive worldwide license rights for highly innovative EGFR ectodomain mutations that have shown to determine response to targeted therapy for patients with metastatic colorectal cancer1 (mCRC).